Incidence Of Surgery For Inflammatory Bowel Disease Within 12 Months Of Initiation Of Vedolizumab Or Infliximab

Autor:	Haridarshan Patel, M Raluy-Callado, Javaria Mona Khalid, Raymond J. Carroll, A Berger
Rok vydání:	2017
Předmět:	medicine.medical_specialty business.industry Health Policy Incidence (epidemiology) Public Health Environmental and Occupational Health medicine.disease Gastroenterology Inflammatory bowel disease Infliximab Vedolizumab Internal medicine medicine business medicine.drug
Zdroj:	Value in Health. 20:A632
ISSN:	1098-3015
DOI:	10.1016/j.jval.2017.08.1412
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6e2d3554568f927c194ebe7c26cf74d1 https://doi.org/10.1016/j.jval.2017.08.1412 Zobrazit plný text záznamu Full Text from ScienceDirect